Reading the tape
NASDAQ: RAPP
Rapport Therapeutics, Inc. Common Stock
Healthcare · Biotechnology
Market Cap
$1.30B
52w High
$42.27
52w Low
$7.73
P/E
-14.97
Volume
327.43K
Outstanding Shares
36.50M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 223.59%FCF (TTM): -30.77%
What changed
The stock rose 223.59% over the last year. Free cash flow declined 30.77% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
CEOAbraham N. Ceesay
SectorHealthcare
IndustryBiotechnology
Employees69
IPO dateJun 7, 2024
Valuation
Forward P/E—
EV/EBITDA-11.16
Enterprise value$1.38B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-23%▲10.28%vs FY2024
Analyst consensus
RatingBuy
Target price$49.00▲37.91%
5
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.62 · Revenue est $7.5M
View